Healthcare provider profile · identity verified

Alejandro Lopez-Rossitch, MD

Internal Medicine · MIAMI, FL · NPI 1528282167

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	630	202
Rosuvastatin Calcium	Rosuvastatin Calcium	370	115
Amlodipine Besylate	Amlodipine Besylate	293	96
Levothyroxine Sodium	Levothyroxine Sodium	262	85
Losartan Potassium	Losartan Potassium	242	86
Alprazolam	Alprazolam	228	58
Omeprazole	Omeprazole	217	75
Metformin Hcl	Metformin Hcl	179	59
Pantoprazole Sodium	Pantoprazole Sodium	170	55
Metoprolol Succinate	Metoprolol Succinate	161	56
Lisinopril	Lisinopril	159	51
Azithromycin	Azithromycin	145	104
Escitalopram Oxalate	Escitalopram Oxalate	142	44
Ezetimibe	Ezetimibe	139	47
Fluticasone Propionate	Fluticasone Propionate	132	80
Famotidine	Famotidine	117	36
Gabapentin	Gabapentin	115	46
Hydrochlorothiazide	Hydrochlorothiazide	106	38
Ozempic	Semaglutide	99	19
Tamsulosin Hcl	Tamsulosin Hcl	85	24
Metformin Hcl Er	Metformin Hcl	80	23
Montelukast Sodium	Montelukast Sodium	79	23
Vascepa	Icosapent Ethyl	79	18
Alendronate Sodium	Alendronate Sodium	76	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	74	22
Sildenafil Citrate	Sildenafil Citrate	69	17
Allopurinol	Allopurinol	68	19
Ibandronate Sodium	Ibandronate Sodium	66	18
Sertraline Hcl	Sertraline Hcl	65	17
Potassium Chloride	Potassium Chloride	63	19
Benzonatate	Benzonatate	59	47
Farxiga	Dapagliflozin Propanediol	59	19
Folic Acid	Folic Acid	58	19
Furosemide	Furosemide	56	20
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	55	18
Clopidogrel	Clopidogrel Bisulfate	53	18
Januvia	Sitagliptin Phosphate	53	15
Valsartan	Valsartan	53	17
Eliquis	Apixaban	51	17
Atenolol	Atenolol	50	16
Ciclopirox	Ciclopirox	48	17
Metoprolol Tartrate	Metoprolol Tartrate	48	15
Olmesartan Medoxomil	Olmesartan Medoxomil	48	15
Tizanidine Hcl	Tizanidine Hcl	48	33
Meloxicam	Meloxicam	42	15
Zolpidem Tartrate	Zolpidem Tartrate	41	12
Prolia	Denosumab	40	22
Albuterol Sulfate Hfa	Albuterol Sulfate	39	15
Carvedilol	Carvedilol	39	12
Simvastatin	Simvastatin	39	14
Finasteride	Finasteride	38	11
Temazepam	Temazepam	38	suppressed
Nebivolol Hcl	Nebivolol Hcl	36	suppressed
Synthroid	Levothyroxine Sodium	36	14
Jardiance	Empagliflozin	34	suppressed
Methylprednisolone	Methylprednisolone	34	29
Ciprofloxacin Hcl	Ciprofloxacin Hcl	33	30
Tramadol Hcl	Tramadol Hcl	33	13
Ketoconazole	Ketoconazole	31	14
Mirtazapine	Mirtazapine	31	suppressed
Diclofenac Sodium	Diclofenac Sodium	30	11
Glimepiride	Glimepiride	30	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Pregabalin	Pregabalin	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	11
Glipizide	Glipizide	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Lorazepam	Lorazepam	29	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	29	29
Cefdinir	Cefdinir	28	22
Dicyclomine Hcl	Dicyclomine Hcl	28	14
Irbesartan	Irbesartan	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Clobetasol Propionate	Clobetasol Propionate	27	11
Celecoxib	Celecoxib	26	suppressed
Telmisartan	Telmisartan	26	suppressed
Trijardy Xr	Empaglifloz/Linaglip/Metformin	26	suppressed
Ammonium Lactate	Ammonium Lactate	25	13
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	24	suppressed
Prednisone	Prednisone	24	15
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	23	11
Enalapril Maleate	Enalapril Maleate	23	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	23	suppressed
Clonazepam	Clonazepam	22	suppressed
Hydrocortisone	Hydrocortisone	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	19	suppressed
Meclizine Hcl	Meclizine Hcl	18	12
Myrbetriq	Mirabegron	18	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Tresiba Flextouch U-100	Insulin Degludec	16	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	15	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	14	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Bumetanide	Bumetanide	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Nateglinide	Nateglinide	13	suppressed
Nystatin	Nystatin	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Ramipril	Ramipril	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Tiadylt Er	Diltiazem Hcl	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Ciclopirox	Ciclopirox Olamine	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Raloxifene Hcl	Raloxifene Hcl	11	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error